Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bird Flu Vaccine from Sinovac Reports Success

publication date: Dec 24, 2007

Sinovac Biotech Ltd. released positive data from a Phase II clinical trial of its pandemic flu (H5N1) vaccine. In the stratified, randomized, double-blind test, the top two dosage levels of Sinovac’s vaccine met the EMEA evaluation standards for seasonal flu vaccines. The trial did not discover any safety problems. Sinovac said it would use the Phase II results of the whole viron vaccine to determine dosing levels for the Phase III tests. More details...

Stock symbol: (AMEX: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital